Clinical Trial Update: An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes an extension study of Treprostinil Palmitil Inhalation Powder (TPIP) for pulmonary arterial hypertension. The trial spans P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Treprostinil Palmitil Inhalation Powder (TPIP) (treprostinil palmitil inhalation powder)

Snippet

Sponsor: Insmed Incorporated | Conditions: Pulmonary Arterial Hypertension | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING